beta-苯基-1,N2-乙烯桥-8-溴鸟苷-3',5'-环单硫代磷酸酯Rp-异构体钠盐 | 172806-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: beta-苯基-1,N2-乙烯桥-8-溴鸟苷-3',5'-环单硫代磷酸酯Rp-异构体钠盐
• 中文别名: 2-溴-3,4-二氢-3-[3,5-O-[(S)-巯基亚膦酰亚基]-beta-D-呋喃核糖基]-6-苯基-9H-咪唑并[1,2-a]嘌呤-9-酮
• 英文名称: 3-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one
• CAS: 172806-20-1；172806-21-2
• 化学式: C₁₈H₁₅BrN₅O₆PS
• 分子量: 540.3
• InChiKey: DBYADRPTMRXVDJ-QJYCJHSLSA-N

物化性质

• 熔点：
  240-300 °C(lit.)
• 沸点：
  888.2±75.0 °C(Predicted)
• 密度：
  2.25±0.1 g/cm3(Predicted)
• 溶解度：
  H2O:15 mg/mLat ≤60 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  32
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  9

安全信息

• WGK Germany：
  3
• 安全说明：
  S22,S24/25

文献信息

• Targeted liposomal delivery of cGMP analogues
  申请人：Mireca Medicines GmbH

  公开号：US10322087B2

  公开（公告）日：2019-06-18

  The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′, 5′-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

  本发明涉及将治疗剂靶向输送到血眼屏障并穿过血眼屏障的手段和方法。特别是，本发明涉及环鸟苷-3′，5′-单磷酸类似物作为治疗视网膜疾病的治疗剂。环鸟苷-3′，5′-单磷酸类似物通过谷胱甘肽配体靶向血眼屏障，促进与存在于血眼屏障上的谷胱甘肽转运体的特异性结合和增强内化。谷胱甘肽配体与包裹 cGMPSs 的脂质体等纳米容器共轭。
• TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES
  申请人：Mireca Medicines GmbH

  公开号：EP3270889A1

  公开（公告）日：2018-01-24
• [EN] TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES<br/>[FR] ADMINISTRATION LIPOSOMALE CIBLÉE D'ANALOGUES DE GMPC
  申请人：EBERHARD KARLS UNIVERSITÄT TÜBINGEN

  公开号：WO2016146669A1

  公开（公告）日：2016-09-22

  The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3', 5 '-monophosphate analogues as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.